Open an account

Biora Therapeutics

BIORQ · OTC

$0.0001−$0.0001 (−50.00%)TodayMarket closed ·
No price history for this range.

About BIORQ

Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. The company is headquartered in San Diego, California and currently employs 58 full-time employees. The company went IPO on 2020-06-19. The Company’s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. The company has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.

Employees
58
Headquarters
San Diego, California
Listed
Jun 19, 2020
Sector
Health Care
Industry
Biotechnology
Website
bioratherapeutics.com

BIORQ key statistics

Market cap
452
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
430
Volume
3
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.003
52 Week low
$0.00

Biora Therapeutics (BIORQ) at a glance

Biora Therapeutics (BIORQ) last traded at $0.0001, with a market cap of 452 and a price-to-earnings ratio of 0.00.

Volume so far is 3 shares, below the average of 430 shares a day.

Over the past year Biora Therapeutics has ranged from $0.00 to $0.003, and now sits 3% of the way up that range.

Biora Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q3 FY24 it reported -$5.04 per share against an estimate of -$3.97.

BIORQ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 70.1% on average.

  1. Q3 FY22: reported -$7.50 per share against an estimate of -$19.31
  2. Q4 FY22: reported -$16.40 per share against an estimate of -$14.88
  3. Q2 FY23: reported -$14.70 per share against an estimate of -$16.48
  4. Q3 FY23: reported -$48.90 per share against an estimate of -$9.53
  5. Q4 FY23: reported -$6.20 per share against an estimate of -$6.13
  6. Q1 FY24: reported -$1.40 per share against an estimate of -$4.64
  7. Q2 FY24: reported $1.80 per share against an estimate of -$4.64
  8. Q3 FY24: reported -$5.04 per share against an estimate of -$3.97

BIORQ news

  • Press releasePRNewswire

    Glancy Prongay & Murray LLP Announces the Proposed Class Action Settlement on Behalf of Purchasers of Progenity, Inc. n/k/a Biora Therapeutics, Inc. common stock - BIORQ

Similar companies

Companies in the same industry as Biora Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.